Gastroenterology
End Stage Liver Disease
6
Pipeline Programs↗
1
Active Trials↗
3
Companies Involved↗
End Stage Liver Disease is an early-stage landscape with 6 programs across 3 companies. The most active players are Merck & Co., Novartis, Melinta Therapeutics, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 1
No programs
Phase 24
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
6
clinical trials
Unknown status3 · 50%
Terminated1 · 17%
Active, not recruiting1 · 17%
Completed1 · 17%
Clinical Trials
Trial Activity
6 trials
Tocotrienol Against the Progression of End Stage Liver Disease
Active, not recruiting·—·Phase 2·NCT02581085·70 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)